- •Scarce evidence comparing brain atrophy in positive and negative AQP4 patients.
- •Brain and lesion volume measurements taken by automated software.
- •Analysis performed in a Latin American population.
- •No differences in lesion distribution at onset and brain volumes during follow-up.
- •Differences observed in lesion distribution and brain volumes between NMOSD and MS.
There is scarce evidence comparing the behavior in magnetic resonance (MRI) between positive and negative aquaporin-4 antibody neuromyelitis optica spectrum disorders (P-NMOSD and N NMOSD, respectively). The aim of this study was to describe and compare MRI features through a quantitative and qualitative analysis between P-NMOSD and NNMOSD patients in a cohort from Latin American (LATAM) patients.
We retrospectively reviewed the MRI and medical records of NMOSD patients as defined by the 2015 validated diagnostic criteria, and with at least 3 years of follow-up from disease onset (first symptom). We included patients from Argentina, Brazil and Venezuela. To be included, NMOSD patients must have had AQP4-ab status measured by a cell-based assay. Brain MRIs were obtained for each participant at disease onset and every 12 months for 3 years. Demographics, clinical and MRI variables (T2 lesion volume [T2LV], lesion distribution, cortical thickness [CT] and percentage of brain volume loss [PBVL]) were analyzed and compared between groups (P-NMOSD; NNMOSD) at disease onset and follow-up. A multiple sclerosis (MS) control group of patients was also included.
We included 24 P-NMOSD, 15 NNMOSD and 35 MS patients. No differences in age, gender and follow-up time were observed between groups. Nor were differences found in lesion distribution at disease onset or in brain volumes during follow-up between P-NMOSD and NNMOSD patients (T2LV = 0.43, CT = 0.12, PBVL p = 0.45). Significant differences were observed in lesion distribution at disease onset, as well as in brain volumes during follow-up between NMOSD and MS (T2LV = p<0.001, CT = p<0.001, PBVL p = 0.01).
Different MRI features were observed between MS and NMOSD. However, no quantitative nor qualitative differences were observed between P-NMOSD and NNMOSD, not allowing us to differentiate NMOSD conditions by MRI.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.Lancet. 2004; 364: 2106-2112
- The spectrum of neuromyelitis optica.Lancet Neurol. 2007; 6: 805-815
- Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases.Continuum (N Y). 2019; 25: 815-844
- Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.Neurology. 2012; 79: 1273-1277
- Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.Neurology. 2014; 83: 1122
- The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.Mult. Scler. 2014; 20: 695-704
- Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.Neurology. 2013; 80: 1330-1337
- MRI characteristics of neuromyelitis optica spectrum disorder: an international update.Neurology. 2015; 84: 1165-1173
- Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients.Mult. Scler. 2019; 1352458519849517
- Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort.J. Neurol. 2020;
- Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.Mult. Scler. Relat. Disord. 2018; 25: 246-250
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.Neurology. 2015; 85: 177-189
- Diagnosis of multiple sclerosis: 2017 revisions of the Mcdonald criteria.Lancet Neurol. 2018; 17: 162-173
- Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.Lancet Neurol. 2005; 4: 281-288
- Admixture dynamics in Hispanics: a shift in the nuclear genetic ancestry of a South American population isolate.Proc. Natl. Acad. Sci. USA. 2006; 103: 7234-7239
- Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.Neuroimage. 2002; 17: 479-489
- Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm.IEEE Trans. Med. Imaging. 2001; 20: 45-57
- Normalized accurate measurement of longitudinal brain change.J. Comput. Assist. Tomogr. 2001; 25: 466-475
- Future MRI tools in multiple sclerosis.J. Neurol. Sci. 2013; 331: 14-18
- Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis.J. Neurol. 2013; 260: 2458-2471
- Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited siena and sienax.J. Magn. Reson. Imaging. 2007; 26: 881-885
- Widespread cortical thinning characterizes patients with MS with mild cognitive impairment.Neurology. 2010; 74: 321-328
- Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis.Eur. J. Neurol. 2017; 24: 437-445
- Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder.Eur. J. Neurol. 2016; 23: 1165-1173
- Structural MRI substrates of cognitive impairment in neuromyelitis optica.Neurology. 2015; 85: 1491-1499
- Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS.Neuroimage. 2006; 30: 891-898
- Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis.Neuroimage. 2007; 36: 1294-1300
- Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.Neurology. 2014; 82: 474-481
- Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IGG versus MOG-IGG seropositive cases in the Netherlands.Eur. J. Neurol. 2016; 23: 580-587
- Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.JAMA Neurol. 2014; 71: 276-283
- Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: a cohort of Latin American patients.Mult. Scler. Relat. Disord. 2018; 19: 73-78
- Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.J. Neurol. Neurosurg. Psychiatr. 2017; 88: 132-136
Souplet, J. C., Lebrun-Frenay, C., Ayache, N.& Malandain, G., 2020. An Automatic Segmentation of T2FLAIR Multiple Sclerosis Lesions Release 0.00.
Published online: March 14, 2020
Accepted: March 8, 2020
Received in revised form: February 4, 2020
Received: December 2, 2019
© 2020 Elsevier B.V. All rights reserved.